ALLInBio

ALLInBio is a private, preclinical-stage biotech founded in 2020 and based in San Francisco. The company is pioneering a precision-medicine strategy for chronic inflammatory and immunological (I&I) diseases, moving away from the current trial-and-error standard of care. By leveraging genetics and likely AI/ML tools, it seeks to identify patients at high risk for severe disease progression and intervene therapeutically before advanced clinical manifestation. This approach targets a significant unmet need where many patients fail to achieve remission with existing treatments.

A precision immunology platform integrating AI/ML for patient stratification using genetic and molecular data to identify 'at-risk' populations for early intervention with targeted biologics.

Competes with large pharmaceutical companies with broad immunosuppressants and a growing pipeline of targeted biologics. Also faces competition from other precision medicine and AI-driven biotechs focused on immunology. The novel focus on very early, preventive treatment is a differentiating but unproven strategy.